ArticleNMR in biomedicine2026
Radiation Effects on Normal Brain in Subjects With Recurrent Glioblastoma by Spectroscopic MRI.
Article in NMR in biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults and almost always recurs. In recurrent GBM, conventional MRI has limited ability to detect microscopic tumor infiltration and distinguish progression from treatment-related change. Spectroscopic MRI (sMRI) provides quantitative metabolic maps across much of the brain, including choline (Cho) and N-acetylaspartate (NAA), a marker of healthy tissue. Because Cho/NAA is commonly used to define metabolically abnormal tissue, and prior radiation therapy (RT) can alter metabolite levels, we evaluated whether prior RT shifts baseline Cho/NAA in recurrent disease. We retrospectively studied 20 patients with recurrent GBM previously treated with maximal safe resection, RT, and temozolomide who underwent whole-brain sMRI at recurrence. The median interval from RT completion to sMRI was 8.99 months. T1-weighted images were co-registered to sMRI in MIDAS and aligned with planning CT in MIM to generate radiation dose maps. MIDAS generated tissue-water-referenced Cho, NAA, and creatine (Cr) maps, and Cho/NAA was normalized to contralateral normal-appearing white matter. Voxel-wise linear regression was performed between prior radiation dose and metabolite values at recurrence. Higher prior dose was associated with reduced NAA (-0.26%/Gy, r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.